LL-37 vs KPV
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Cathelicidin, CAP18
A naturally occurring antimicrobial peptide and the only human cathelicidin. Part of the innate immune system with broad-spectrum antimicrobial activity.
Also: Lys-Pro-Val, Alpha-MSH fragment
A tripeptide derived from alpha-melanocyte stimulating hormone (α-MSH). Known for potent anti-inflammatory effects, particularly in the gut.
Key Comparison Insights
- Both peptides belong to the Immune category, suggesting similar primary applications.
- LL-37 has stronger research evidence (Human Trials) compared to KPV (Animal Studies).
Detailed Comparison
| Attribute | LL-37 | KPV |
|---|---|---|
| Category | Immune | Immune |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | LL-37 directly kills bacteria, fungi, and some viruses by disrupting their cell membranes. It also modulates the immune response, promotes wound healing, reduces inflammation, and has anti-biofilm activity against bacterial infections. | KPV retains the anti-inflammatory properties of α-MSH without melanocortin receptor activation. It inhibits inflammatory pathways including NF-κB, reduces pro-inflammatory cytokines, and has antimicrobial properties. |
| Common Dosing | 100-200 mcg daily Once daily | 200-500 mcg daily 1-2x daily |
| Administration | Subcutaneous injection or topical | Subcutaneous injection or oral (capsules) |
| Typical Duration | Variable by protocol | 4-8 weeks typical |
| Best Time to Take | Morning | Morning or as directed |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Research demonstrates broad antimicrobial activity including against antibiotic-resistant bacteria. Studies show wound healing benefits, anti-biofilm effects, and immune modulation. Being investigated for chronic infections and wound healing applications. | Studies show effectiveness in inflammatory bowel disease models. Research demonstrates wound healing acceleration and antimicrobial activity. Being investigated for gut health and inflammatory conditions. |
Frequently Asked Questions: LL-37 vs KPV
What is the difference between LL-37 and KPV?
LL-37 is a immune peptide that a naturally occurring antimicrobial peptide and the only human cathelicidin. part of the innate immune system with broad-spectrum antimicrobial activity. KPV is a immune peptide that a tripeptide derived from alpha-melanocyte stimulating hormone (α-msh). known for potent anti-inflammatory effects, particularly in the gut. The main differences lie in their mechanisms of action and clinical applications.
Which is better, LL-37 or KPV?
Neither is universally "better" - the choice depends on your specific goals. LL-37 is typically used for immune purposes, while KPV is used for immune. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can LL-37 and KPV be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using LL-37 and KPV together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.